Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)

Lantheus Holdings' (LNTH) quarterly Net Income towards Common Stockholders came in at $118.4 million in Q1 2026, up 62.34% year-on-year from $72.9 million in Q1 2025, and up 118.93% on a QoQ basis from $54.1 million in Q4 2025.

Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has 13 years of Net Income towards Common Stockholders data on file, last reported at $118.4 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 62.34% year-over-year to $118.4 million in Q1 2026; TTM through Mar 2026 was $279.0 million, a 9.72% increase from a year earlier, with the FY2025 full-year figure at $233.6 million, down 25.25% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at $118.4 million, up from $54.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for LNTH reached as high as $132.0 million in Q3 2023 and fell as low as -$119.2 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged $59.8 million across 5 years, with a median of $62.1 million in 2024.
  • Across the five-year window, Net Income towards Common Stockholders slumped 196.37% in 2022 and surged 4769.26% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$119.2 million in 2022, then surged by 185.05% to $101.4 million in 2023, then sank by 111.63% to -$11.8 million in 2024, then soared by 558.76% to $54.1 million in 2025, then soared by 118.93% to $118.4 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 91.93 Bn 90.07 Bn - -
2 Teva Pharmaceutical Industries 36.31 Bn 32.57 Bn 1.97 Bn 370.00 Mn
3 Zoetis 33.01 Bn 31.07 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.65 Bn 23.59 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.96 Bn 20.81 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.50 Bn 18.69 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 18.16 Bn 16.85 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.84 Bn 12.41 Bn 785.00 Mn 57.00 Mn
10 Lantheus Holdings 6.58 Bn 6.08 Bn 230.92 Mn 118.42 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 118.42 Mn
Dec 31, 2025 54.09 Mn
Sep 30, 2025 27.77 Mn
Jun 30, 2025 78.76 Mn
Mar 31, 2025 72.95 Mn
Dec 31, 2024 -11.79 Mn
Sep 30, 2024 131.09 Mn
Jun 30, 2024 62.07 Mn
Mar 31, 2024 131.07 Mn
Dec 31, 2023 101.36 Mn
Sep 30, 2023 131.96 Mn
Jun 30, 2023 94.13 Mn
Mar 31, 2023 -2.81 Mn
Dec 31, 2022 -119.19 Mn
Sep 30, 2022 61.23 Mn
Jun 30, 2022 43.06 Mn
Mar 31, 2022 42.96 Mn
Dec 31, 2021 -40.22 Mn
Sep 30, 2021 -13.42 Mn
Jun 30, 2021 -26.66 Mn